Skip to main content
Caplight Logo









EviCure

EviCure

Private
Ness ZionaHealthcare & Life Scienceshttps://evicure.bio

Last Round

Seed

May 15, 2023

Company Overview

EviCure operates in Healthcare & Life Sciences and is based in Ness Ziona. Its latest recorded funding round was a Seed round in May 2023.

EviCure is a biotechnology company that develops an artificial intelligence-driven platform for the production of extracellular vesicle-based therapies to treat solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

EviCure Comparables

Compare EviCure with similar companies based on industry and business-model similarity.

EviCure comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vanquish Bio
79%
ExoVectory
78%
ILIAS Biologics Inc.
77%
Book a demo to see all comparables

For institutional investors. Book with your work email.

EviCure Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 15, 2023
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Eric J. Messika

Chief Executive Officer

Executive Team

For institutional investors. Book with your work email.

EviCure Investors

Notable investors and investment history

EviCure investors
InvestorRounds
Peregrine VenturesVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2023

    Peregrine Ventures led the Seed round.

Book a demo to see all signals

For institutional investors. Book with your work email.

EviCure Filings

Explore SEC and related filing metadata, where available.

EviCure filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about EviCure's valuation, stock price, and market status.

Is EviCure a public or private company?

EviCure is a private company.

What is the current stock price of EviCure?

EviCure is a private company, so its shares have no public market price. Caplight tracks EviCure's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is EviCure worth (valuation)?

Valuation information for EviCure is not publicly available.

Can I buy EviCure stock?

EviCure shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was EviCure's last funding round?

EviCure's most recent funding round was Seed on May 15, 2023.

Who are the main investors in EviCure?

Key investors in EviCure include Peregrine Ventures.

Will EviCure IPO soon?

No public IPO plans have been announced for EviCure.

How can I track EviCure secondary market activity?

Caplight tracks bids, offers, and trades in EviCure's shares on secondary markets.

Firmographic Details

HeadquartersNess Ziona
Employee Range2
Year Founded2023
Last FundingMay 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?